Anika Therapeutics (NASDAQ:ANIK) Announces Earnings Results, Misses Estimates By $0.13 EPS

Anika Therapeutics (NASDAQ:ANIK) posted its earnings results on Wednesday. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.13), Zacks reports. Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%.

Anika Therapeutics Trading Up 1.9 %

Shares of ANIK traded up $0.32 during trading hours on Wednesday, hitting $17.11. The company had a trading volume of 113,756 shares, compared to its average volume of 68,231. Anika Therapeutics has a one year low of $15.40 and a one year high of $29.11. The company’s fifty day moving average price is $16.91 and its two-hundred day moving average price is $19.66. The company has a market capitalization of $250.59 million, a PE ratio of -2.57 and a beta of 0.95.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.